Evidence map›Paper›PMID 30348101›Full record

Trial reportBMC cardiovascular disorders2018

Effect of tailored use of tirofiban in patients with Non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention: a randomized controlled trial.

Wonjae Lee, Jung-Won Suh, Jin Joo Park, Chang-Hwan Yoon, Young-Seok Cho, Tae-Jin Youn, In-Ho Chae

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC cardiovascular disorders, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03114995 (Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03114995 phase4completednot on this map

Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

TypeinterventionalSponsorSeoul National University Bundang HospitalRan2012 to 2015Enrolled140ConditionsNon-ST Elevation Myocardial InfarctionArmsTirofiban
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wonjae LeeDivision of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University, Seongnam-si, Gyeonggi-do, Korea.
Jung-Won SuhDivision of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University, Seongnam-si, Gyeonggi-do, Korea.
Jin Joo ParkDivision of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University, Seongnam-si, Gyeonggi-do, Korea.
Chang-Hwan YoonDivision of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University, Seongnam-si, Gyeonggi-do, Korea.
Young-Seok ChoDivision of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University, Seongnam-si, Gyeonggi-do, Korea.
Tae-Jin YounDivision of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University, Seongnam-si, Gyeonggi-do, Korea. ytjmd@snubh.org.ORCID 0000-0001-9957-4204
In-Ho ChaeDivision of Cardiology, Department of Internal Medicine, College of Medicine, Seoul National University, Seongnam-si, Gyeonggi-do, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe conducted a randomized controlled trial to investigate whether an additional platelet inhibition with tirofiban would reduce the extent of myocardial damage and prevent periprocedural myonecrosis in patients with Non-ST-elevation acute coronary syndrome (NSTE-ACS) with a high residual platelet activity (HPR).

methodsPatients with an HPR, defined as P

resultsThe troponin I AUC was not different between the groups (197.2 [41.5395.7], 37.9 [8.9313.9], 121.3 [43.7481.8] h∙ng/mL; p = 0.088). The results did not change when the baseline levels were adjusted (365.3 [279.5, 451.1], 293.0 [207.1, 379.0], and 298.0 [244.7, 351.3] h∙ng/mL; p = 0.487). The rate of periprocedural myonecrosis was also not different between the groups (53.0% vs. 50.0% vs. 33.3%, p = 0.092). The CK-MB isoenzyme analysis showed similar results. No difference in complications was noted.

conclusionAdditional tirofiban administration was not beneficial to patients with NSTE-ACS even with an HPR.

trial registrationClinical trial no. NCT03114995 , registered 11 April, 2017, retrospectively.

Indexed as

Percutaneous Coronary InterventionAcute Coronary SyndromeAgedAged, 80 and overAspirinBiomarkersClopidogrelCoronary AngiographyCreatine Kinase, MB FormDrug ResistanceFemaleHumansMaleMiddle AgedMyocardiumNecrosisAspirinBiomarkersClopidogrelCreatine Kinase, MB FormPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsTirofibanTroponin IGlycoprotein IIb/IIIa inhibitorHigh residual platelet activityPeriprocedural myonecrosisTailored antiplatelet treatment

Identifiers

PMID30348101
PMCPMC6198526

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.